Islet amyloid polypeptide in pancreatic islets from type 2 diabetic subjects

Islets

Volumn 4, Issue 3, 2012, Pages 223-232

  Tomita, Tatsuo ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Amyloid deposit; Immunocytochemistry; Islet amyloid polypeptide; Pancreatic islets; Type 2 diabetes

Indexed keywords

AMYLIN; AMYLIN ANTIBODY; GLUCAGON; INSULIN; PROTEIN ANTIBODY; SOMATOSTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL COMPOSITION; CELL DEATH; CELL GRANULE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLUCAGONEMIA; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET DELTA CELL;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; SOMATOSTATIN;

EID: 84864400342     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.20477     Document Type: Article

References (52)

1. Opie EL. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of langerhans. J Exp Med 1901; 5:527-40; PMID:19866956; http://dx.doi.org/10.1084/jem.5.5.527.
2. Ehrlich JC, Ratner IM. Amyloidosis of the islets of Langerhans. A restudy of islet hyalin in diabetic and non-diabetic individuals. Am J Pathol 1961; 38:49-59; PMID:13726023.
3. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9:151-9; PMID:3073901.
4. Röcken C, Linke RP, Saeger W. Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch A Pathol Anat Histopathol 1992; 421:339-44; PMID:1413495; http://dx.doi.org/10.1007/BF01660981.
5. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140:827-31; PMID:3535798; http://dx.doi.org/10.1016/0006-291X(86)90708-4.
6. Cooper GJ, Willis AC, Clark A, Tumer RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic pancreas. Proc Natl Acad Sci USA 1987; 84:8628-32; http://dx.doi.org/10.1073/ pnas.84.23.8628.
7. Kahn SE, Andrikopoulos S, Verchere CBN. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48:241-53; PMID:10334297; http://dx.doi.org/10.2337/diabetes.48.2.241.
8. Höppener JW, Ahrén B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343:411-9; PMID:10933741; http://dx.doi.org/10.1056/NEJM200008103430607.
9. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999; 25:389-97; PMID:10531859; http://dx.doi.org/10.1177/014572179902500310.
10. Tomita T. Islet amyloid polypeptide in pancreatic islets from type 1 diabetic subjects. Islets 2011; 3:166-74; PMID:21633185; http://dx.doi.org/10. 4161/isl.3.4.15875.
11. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7:1353-73; PMID:11472273; http://dx.doi.org/10.2174/1381612013397357.
12. Buse JB, Weyer C, Maggis DC. Amylin replacement with Pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002; 20:137-44; http://dx.doi.org/10.2337/ diaclin.20.3.137.
13. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. HormMetab Res 2002; 34:504-8; PMID:12384827; http://dx.doi.org/10.1055/s-2002-34790.
14. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629-43. (Pubitemid 39071447)
15. Lorenzo A, Razzaboni B, Weir GC, Yankner BA. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368:756-60; PMID:8152488; http://dx.doi.org/10.1038/368756a0.
16. Jaikaran ET, Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001; 1537:179-203; PMID:11731221.
17. Marzban L, Park K, Verchere CB. Islet amyloid polypeptide and type 2 diabetes. Exp Gerontol 2003; 38:347-51; PMID:12670620; http://dx.doi.org/10. 1016/S0531-5565(03)00004-4.
18. Hayden MR. Islet amyloid, metabolic syndrome and the natural progressive history of type 2 diabetes mellitus. JOP 2002; 3:126-38; PMID:12221327.
19. Kloppel G, Lenzen S. Anatomy and physiology of the endocrine pancreas. In: Kloppel G, Heitz PU, Editors. Pancreatic Pathology. Edinburgh, Churchill-Livingstone 1984; 133-53.
20. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004; 88:787-835; PMID:15308380; http://dx.doi.org/10.1016/j.mcna.2004.04.013.
21. Tomita T. Immunocytochemical localization of capase-3 in pancreatic islets from type 2 diabetic subjects. Pathology 2010; 42:432-7; http://dx.doi.org/10.3109/00313025.2010.493863.
22. Clark A, Nilsson MR. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004; 47:157-69; PMID:14722650; http://dx.doi.org/10.1007/s00125-003-1304-4.
23. Tomita T. Amyloidosis of pancreatic islets in primary amyloidosis (AL type). Pathol Int 2005; 55:223-7; PMID:15826250; http://dx.doi.org/10.1111/j. 1440-827.2005.01815.x.
24. Mirzabekov TA, Lin MC, Kagan BL. Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 1996; 271:1988-92; PMID:8567648; http://dx.doi.org/10.1074/jbc.271.4.1988.
25. Anguiano M, Nowak RJ, Lansbury PT Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002; 41:11338-43; PMID:12234175; http://dx.doi.org/10.1021/bi020314u.
26. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48:491-8; PMID:10078548; http://dx.doi.org/10.2337/diabetes.48.3.491.
27. Engel MFM, Khemtémourian L, Kleijer CC, Meeldijk HJ, Jacobs J, Verkleij AJ, et al. Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane. Proc Natl Acad Sci USA 2008; 105:6033-8; PMID:18408164; http://dx.doi.org/10.1073/pnas.0708354105.
28. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008; 29:303-16; PMID:18314421; http://dx.doi.org/10.1210/er.2007-0037.
29. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-9; PMID:12702875; http://dx.doi.org/10.1126/ science.1079469.
30. Bonner-Weir S, O'Brien TD. Islets in type 2 diabetes: in honor of Dr. Robert C. Turner. Diabetes 2008; 57:2899-904; PMID:18971437; http://dx.doi.org/10.2337/db07-1842.
31. Westermark P. Fine structure of islets of Langerhans in insular amyloidosis. Virchows Arch A Pathol Pathol Anat 1973; 359:1-18; PMID:4632997; http://dx.doi.org/10.1007/BF00549079.
32. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5:2145-54; PMID:1850705.
33. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4:197-250; PMID:8435466.
34. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9:541-73; PMID:8280471; http://dx.doi.org/10.1146/annurev.cb.09.110193. 002545.
35. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-4; PMID:10419448; http://dx.doi.org/10.1074/jbc.274.31.21491.
36. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res 2003; 92:827-39; PMID:12730128; http://dx.doi.org/10.1161/01.RES.0000070112.80711.3D.
37. Perez SE, Cano DA, Dao-Pick T, Rougier JP, Werb Z, Hebrok M. Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Diabetes 2005; 54:694-701; PMID:15734845; http://dx.doi.org/ 10.2337/diabetes.54.3.694.
38. Tomita T. Caspase-3 immunocytochemical staining for pancreatic endocrine tumors. Hum Pathol 2009; 40:1050-2; PMID:19427666; http://dx.doi.org/10.1016/j. humpath.2009.02.010.
39. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol 1997; 10:47-54; PMID:9021726.
40. Tomita T. New markers for pancreatic islets and islet cell tumors. Pathol Int 2002; 52:425-32; PMID:12167099; http://dx.doi.org/10.1046/j.1440-827.2002. 01368.x.
41. Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 1987; 57:230-6; PMID:2441141.
42. Law E, Lu S, Kieffer TJ, Warnock GL, Ao Z, Woo M, et al. Differences between amyloid toxicity in alpha and beta cells in human and mouse islets and the role of caspase-3. Diabetologia 2010; 53:1415-27; PMID:20369225; http://dx.doi.org/10.1007/s00125-010-1717-9.
43. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997; 326:1-16; PMID:9337844.
44. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick E, Majluf-Cruz A. Pancreatic islet amyloidosis, β-cell apoptosis and α-cell proliferation and determinants of islet cell remodeling in type 2 diabetic baboons. Proc Natl Acad Sci USA 2009; 106:13992-7; PMID:19666551; http://dx.doi.org/10.1073/pnas.0906471106.
45. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187:587-600; PMID:9463409; http://dx.doi.org/10.1084/jem.187.4.587.
46. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002; 50:449-54; PMID:11897797; http://dx.doi.org/10.1177/ 002215540205000401.
47. Butler AE, Janson J, Bonner-Weir S, Ritzel RT, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-10; PMID:12502499; http://dx.doi.org/10.2337/ diabetes.52.1.102.
48. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54:97-107; http://dx.doi.org/10.2337/diabetes. 54.suppl-2.S97.
49. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1975; 1:14-6; PMID:46337; http://dx.doi.org/10.1016/ S0140-6736(75)92375-2.
50. Stefan Y, Grasso S, Perreltm A, Orci L. The pancreatic polypeptide-rich lobe of the human pancreas; definitive identification of its derivation from the ventral pancreatic primordium. Diabetologia 1982; 23:141-2; http://dx.doi.org/10.1007/BF01271177.
51. Rahier J, Goebbels RM, Henquin JC. Cellular composition of the human diabetic pancreas. Diabetologia 1983; 24:366-71; PMID:6347784; http://dx.doi.org/10.1007/BF00251826.
52. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4:110-25; PMID:3901180.